Skip to content

GenSight Biologics integrates the Enternext PEA-PME 150 index

Paris, France, October 2, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, announces its inclusion, as of today, in the Enternext® PEA-PME 150 index following its annual review.

Please find the full PDF press release attached.

Contacts

GenSight Biologics
Thomas Gidoin
Chief Financial Officer
ir@gensight-biologics.com
+33 (0)1 76 21 72 20
NewCap
I
nvestor Relations
Florent Alba
gensight@newcap.eu
+33 (0)1 44 71 98 55
Rooney Partners
Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

Source: GenSight Biologics